NIH Supports Phase 1 Clinical Trial of Vical's DNA-Based Anthrax Vaccine
SAN DIEGO -- Vical Incorporated announces that the National Institute of Allergy and
Infectious Diseases (NIAID) of the U.S. National Institutes of Health (NIH)
has advised the company that it will support a Phase 1 clinical trial of the
company's investigational plasmid DNA-based anthrax vaccine at two
NIAID-funded Vaccine and Treatment Evaluation Units (VTEUs). Clinical trial
materials are ready for shipment, and the trial is expected to begin within
the next few weeks.
"This partnership with NIAID provides funding and advances our anthrax
vaccine into human clinical testing," said David C. Kaslow, MD, Vical's
chief scientific officer. "Our bivalent vaccine has the potential to provide
broader protection against anthrax than the currently licensed vaccine and
potentially superior stability for stockpiling. In addition, this trial
provides an opportunity to confirm in humans the potent antibody responses
that our vaccine elicited in animal studies."
The VTEUs, established in 1962, are a nationwide network of
university-affiliated research hospitals that conduct Phase 1 and Phase 2
clinical trials for NIAID. Through these centers, candidate vaccines of
potential public health significance are tested and evaluated for safety and
efficacy. The VTEUs have conducted clinical trials of vaccines for numerous
infectious diseases, including those that might be introduced through acts of
bioterrorism.
Vical researches and develops biopharmaceutical products based on its
patented DNA delivery technologies for the prevention and treatment of serious
or life-threatening diseases. Potential applications of the company's DNA
delivery technology include DNA vaccines for infectious diseases or cancer, in
which the expressed protein is an immunogen; cancer immunotherapeutics, in
which the expressed protein is an immune system stimulant; and cardiovascular
therapies, in which the expressed protein is an angiogenic growth factor. The
company has retained all rights to its internally developed product
candidates.
Source: Vical Incorporated
Pioneering Advances in Sterilization: The Future of Infection Control
November 28th 2024Germitec, STERIS, ASP, and Zuno Medical are pioneering sterilization advancements with groundbreaking technologies that enhance SPD workflows, improve patient safety, and redefine infection control standards.
Genomic Surveillance A New Frontier in Health Care Outbreak Detection
November 27th 2024According to new research, genomic surveillance is transforming health care-associated infection detection by identifying outbreaks earlier, enabling faster interventions, improving patient outcomes, and reducing costs.
Point-of-Care Engagement in Long-Term Care Decreasing Infections
November 26th 2024Get Well’s digital patient engagement platform decreases hospital-acquired infection rates by 31%, improves patient education, and fosters involvement in personalized care plans through real-time interaction tools.
Comprehensive Strategies in Wound Care: Insights From Madhavi Ponnapalli, MD
November 22nd 2024Madhavi Ponnapalli, MD, discusses effective wound care strategies, including debridement techniques, offloading modalities, appropriate dressing selection, compression therapy, and nutritional needs for optimal healing outcomes.
